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Abstract
Background and Objective Dupuytren’s contractures
affecting proximal interphalangeal (PIP) joints are chal-
lenging to treat. We explored the effects of collagenase
Clostridium histolyticum (CCH) on PIP joint contractures
after injection of an affected metacarpophalangeal (MP)
joint in the same finger and after injection of an isolated
PIP joint contracture.
Methods Two patient subsets were evaluated: those with
MP/PIP joints contractures in the same finger, but only the
MP joint contractures were treated (Group A); and those
with isolated PIP joint contractures that were treated
(Group B). Endpoints included correction and improve-
ment in contracture. Fixed-flexion contracture (FFC) and
range of motion (ROM) were also assessed; adverse events
(AEs) were monitored.
Results In Group A, 28 and 43 % of PIP contractures
spontaneously corrected after the first and last injection of
CCH, respectively, for MP contractures; 40 and 63 %,
respectively, improved. In Group B, 31 and 39 % of PIP
joint contractures corrected after the first and last injection
of CCH, respectively, 56 and 66 %, respectively,
improved. In Groups A and B, FFC improvements were
largest after the last injection; ROM improvements were
largest after the last injection in Group A and third injec-
tion in Group B. For 46 and 44 % of patients in Groups A
and B, respectively, the first injection was the last injection.
In Group B, the median (minimum, maximum) injections/
joint was 1.0 (1.0, 4.0). Nearly all patients (98 %) experi-
enced C1 AE; most were injection-site reactions.
Conclusions The efficacy of CCH for improving PIP joint
contracture was similar whether treated in isolation or after
treatment of an MP joint contracture.
1 Introduction
In Dupuytren’s disease, the metacarpophalangeal (MP),
proximal interphalangeal (PIP), and distal interphalangeal
(DIP) joints can develop fixed-flexion deformities due to
the development and subsequent contraction of diseased
cords in the affected tissue. Although PIP joints are not
affected as often as are MP joints [1], they can be more
disabling for patients, as many routine, daily activities are
impaired when these joints are contracted [1, 2]. Fre-
quently, PIP joint contracture is accompanied by MP joint
contracture [3]. Research has shown that improvements in
PIP joint contractures correlate positively with improved
hand function [2, 4]. The PIP joint contractures are also
more challenging to treat using corrective surgery [5, 6] or
minimally invasive procedures such as percutaneous nee-
dle fasciotomy (PNF) [2] and collagenase Clostridium
histolyticum (CCH) injections [7]. The CCH injection is the
first non-surgical, pharmacologic treatment for Dupuy-
tren’s contracture (DC) with a palpable cord approved for
M. J. Hayton (&)
Wrightington Hospital, Hall Lane, Appley Bridge,
Lancashire WN6 9EP, UK
e-mail: mikehayton@gmail.com
A. Bayat
Manchester Institute of Biotechnology, University of
Manchester, Manchester, UK
D. S. Chapman
Specialty Care Biostatistics, Pfizer Inc., New York, NY, USA
R. A. Gerber
Medicines Development Group, Pfizer Inc., Groton, CT, USA
P. P. Szczypa
Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK
Clin Drug Investig (2013) 33:905–912
DOI 10.1007/s40261-013-0139-0
use in the USA and Europe. Clinical trials [7–9] and post-
marketing studies [10, 11] have demonstrated the efficacy
and safety of CCH for correcting DC.
In this secondary analysis of data from four large clin-
ical trials, we explored the efficacy of CCH on (1) PIP joint
contractures when only the adjacent MP joint was treated;
and (2) isolated PIP joint contractures treated with CCH.
2 Methods
2.1 Overview of Collagenase Clostridium histolyticum
Studies
CORD (Collagenase Option for Reduction of Dupuytren’s)
I [8] and II [7] were 90-day, phase III trials conducted at 16
sites in the USA and five sites in Australia, respectively.
CORD I also had a 9-month, open-label extension.
JOINT I and II were 9-month, open-label studies con-
ducted at 14 sites in the USA and 20 sites in Europe and
Australia, respectively [9]. For all four studies, eligible
patients (aged C18 years) were required to have a fixed-
flexion deformity in C1 finger (other than the thumb) that
was C20 and B100 in an MP joint or C20 and B80 in a
PIP joint caused by a palpable cord that had not been
previously treated with CCH.
Before treatment in all four studies, investigators
selected the hand to be treated and prioritized all palpable
cords as primary, secondary, and tertiary. The primary cord
could affect an MP or PIP joint if the contracture occurred
solely in these respective joints. If there were contractures
in both the MP and PIP joints of the same finger, the cord
causing the MP contracture was deemed the primary cord.
After the primary joint was successfully treated, either an
MP or PIP joint contracture could be selected. Subsequent
joints were selected on the basis of providing the patient
with full functionality of the treated hand. Patients could
receive a maximum of three injections during the study
period. The primary endpoint was clinical success, defined
as a reduction in contracture of the primary joint to B5 of
full extension 30 days after injection. Secondary endpoints
included clinical improvement, defined as a C50 %
reduction in contracture of a treated joint, and a sponta-
neous effect of treatment, defined as a C20 reduction in
contracture of any other joint not directly treated with
CCH. Changes in fixed-flexion contractures (FFC) and
range of motion (ROM) were also assessed.
2.2 Inclusion Criteria
For this secondary analysis, patients were included if they
had C1 PIP joint contracture at study entry and received
C1 CCH injection during the study. To evaluate the
indirect and direct effects of CCH on PIP joint contrac-
tures, data for two patient subgroups were analyzed. In
Group A, patients had MP and PIP joint contractures in the
same finger, but only the cord affecting the MP joint was
treated with CCH. In Group B, patients had an isolated PIP
joint contracture (or PIP joint contracture combined with
an MP joint contracture\20), and only the cord affecting
the PIP joint was treated with CCH. For brevity throughout
the report, when we refer to a CCH-treated joint, the cord
contracting the joint received the CCH injection(s).
2.3 Assessment of Efficacy and Tolerability
In keeping with the definitions used in the phase III studies,
in Group A, the indirect effects of CCH on PIP joints after
the injection of MP joints were evaluated for correction of
contracture, defined as a reduction in FFC to B5 30 days
after injection, and as a spontaneous treatment effect (i.e.,
improvement), defined as a C20 reduction in FFC 30 days
after injection. In Group B, the direct effects of CCH on
PIP joints were evaluated for correction of contracture, as
defined previously. Improvement in contracture was
defined as a C50 % reduction in FFC from baseline
30 days after injection. The results for joints that corrected
were included in the results for joints that showed
improvement. In both groups, the percentage change in
FFC and mean change in ROM were also assessed. In all
four trials, the adverse events (AEs) were monitored and
recorded for the duration of the studies.
2.4 Statistical Analysis
Although the CORD and JOINT studies differed by design
(i.e., double-blind vs. open-label), all four protocols used
the same inclusion/exclusion criteria to enroll patients, and
the treatment paradigms were virtually identical. More-
over, the respective patient populations were relatively
homogeneous for baseline demographic (e.g., age, sex) and
clinical characteristics (e.g., contracture severity, digits/
joints affected). Thus, it was considered appropriate to pool
all of the relevant data for this analysis. Inferential statistics
were not performed on the data; only descriptive attributes
are reported, including means and standard deviation (SD)
or medians and ranges (minimum, maximum) when
appropriate. The data are reported at the joint level unless
otherwise specified (i.e., patient level, finger level).
3 Results
In total, 616 patients were included in the analysis. Base-
line demographic and clinical characteristics are summa-
rized in Table 1. Mean ± SD age was 63 ± 10 years;
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nearly 70 % of patients were aged 44–74 years. Eighty-
three percent of patients were male, and 100 % were white.
More than 75 % of patients had B2 PIP joints affected;
61 % of patients had B3 joints affected. Isolated PIP joints
in the fifth finger accounted for the largest percentage
(61 %) of affected joints treated with CCH, followed by
combined MP/PIP joint contractures on the fifth finger
(25 %). The distribution of affected MP and PIP joints by
finger is shown in Fig. 1. Nearly half (46 %) of patients
with MP and PIP joint contractures on the same finger
received CCH injections for the MP joint only; 18 %
received CCH injections for the PIP joint contracture, and
36 % received both MP and PIP joint injections. For PIP
joint contractures that received direct CCH injections
(Group B), the median (minimum, maximum) number of
injections per joint overall was 1.0 (1.0, 4.0) [mean ± SD,
1.6 ± 0.8]. The median number of injections per joint for
total correction was 1.0 (1.0, 3.0) [mean ± SD, 1.3 ± 0.6].
In Group A, 28 % of PIP joint contractures spontane-
ously corrected after the first CCH injection for the MP
joint deformity; 43 % of PIP joint contractures were cor-
rected after the last MP joint injection. In Group B, 31 % of
PIP joint contractures were corrected after the first CCH
injection; 39 % were corrected after the last injection
(Fig. 2a). In Group A, 40 % of PIP joints showed
improvement in contracture after the first MP joint injec-
tion; 63 % showed improvement after the last MP joint
injection, which for 46 % (93/201) of cases was also the
first injection. In Group B, 56 % of PIP joints showed
improvements in contracture after the first direct CCH
injection; 66 % showed improvement after the last injec-
tion, which for 44 % (209/376) of cases was also the first
injection (Fig. 2b).
For Group A, the mean change in FFC was 66 % after
the first CCH injection and 77 % after the last injection.
For Group B, the mean change in FFC was 55 % after the
first CCH injection and 62 % after the last injection
(Fig. 3a). In both groups, baseline FFC values were
higher (i.e., more severe contractures) among joints that
received a second or third injection (Table 2). Day 30
values were also higher in both groups. As indicated by
the relative changes, FFC values were lowest after the last
injection in both groups. Data from Table 2 are plotted
graphically in Fig. 4a to show the linear relationship
between baseline PIP joint contracture severity and FFC
measures 30 days after each injection in both groups.
More severe contractures at baseline received two or three
CCH injections, and although the change in FFC from
baseline was dramatic, day 30 FFC measures remained
higher than did those for PIP joints that received only one
CCH injection.
For ROM, the mean ± SD change in Group A was
27.8 ± 19.7 after the first CCH injection and
34.3 ± 19.8 after the last injection; changes in Group B
were 24.4 ± 18.1 after the first CCH injection and
29.1 ± 20.0 after the last injection (Fig. 3b). In both
groups, baseline ROM values were lower among joints that
received a second or third injection (Table 2). The ROM
values were highest after the last injection in Group A and
after the third injection in Group B. Figure 4b shows the
linear relationship between ROM measures at baseline and
30 days after each injection in both groups. Again, despite
notable increases in ROM for all PIP contractures, joints
with more restricted ROM received two or three CCH
injections and the day 30 values were lower than in PIP
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Group A (MP treated) Group B (Isolated PIP)
Fig. 1 Distribution of affected metacarpophalangeal and proximal
interphalangeal joints by finger. MP metacarpophalangeal, PIP
proximal interphalangeal
Table 1 Baseline demographic and clinical characteristics
Variable Value
Patients (N = 616)
Age (years) [mean ± SD] 63 ± 10
Male sex [n (%)] 508 (83)
Joints affected [mean ± SD] 3.3 ± 2.2
PIP joints affected [mean ± SD] 1.9 ± 1.2





Fingers with MP/PIP contractures (N = 416) [n (%)]
Only MP treated 191 (46)
Both MP and PIP treated 150 (36)
Only PIP treated 75 (18)
Joints treated with CCH (N = 577) [n (%)]
MP 201 (35)
PIP 376 (65)
CCH collagenase Clostridium histolyticum, MP metacarpophalangeal,
PIP proximal interphalangeal, SD standard deviation
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3.1 Safety and Tolerability
Nearly all patients (98 %) in the PIP joint contracture
subgroup experienced C1 AE during the study in which
they were enrolled. The majority of AEs were mild, tran-
sient, and localized to the injection site, including periph-
eral edema, pain, hemorrhage, tenderness, and swelling.
The AEs occurring in C10 % of patients in the PIP joint
contracture subgroup and compared with all patients from
the four studies are summarized in Table 3. With one
exception (injection-site pain), slightly larger percentages
of patients in the PIP subgroups experienced AEs com-
pared with all patients from the four clinical studies.
4 Discussion
In this secondary analysis of data from four large clinical
trials of CCH for DC, we explored treatment effects on PIP
joint contractures from two perspectives: (1) spontaneous
correction and/or improvement after CCH injection for an
MP joint contracture affecting the same finger; and (2) cor-
rection and/or improvement after direct injection into a cord
contracting an isolated PIP joint. More than 600 patients
from the CORD I [8] and II [7] trials and the JOINT I and II
studies [9] were included; 201 MP/PIP combination con-
tractures and 376 PIP contractures were evaluated. Isolated
PIP joints in the fifth finger accounted for the largest per-
centage (61 %) of affected joints treated with CCH.
Overall, similar percentages of PIP joint contractures
showed spontaneous correction after CCH injection for a
contracted MP joint in the same finger or after direct CCH
injection of an affected PIP joint (43 and 39 %, respec-
tively). Although improvement in contracture was defined
differently for Group A (i.e., C20 reduction in contracture
30 days after injection) and Group B (i.e., C50 % reduc-
tion in contracture 30 days after injection), comparable
percentages of PIP joint contractures met this endpoint
after CCH injection for a contracted MP joint in the same
finger or after direct CCH injection of an affected PIP joint
(63 and 66 %, respectively).
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Fig. 2 Results for fixed-flexion contracture correction (a) and
improvement (b) after collagenase Clostridium histolyticum by group.
Correction = reduction in contracture to B5 30 days after injection
for both groups; improvement = C20 reduction in contracture
(Group A) or C50 % reduction in contracture (Group B) 30 days
after injection. FFC fixed-flexion contracture, MP metacarpophalan-
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(201) (75) (33) (201)(376) (147) (62) (376)(n)
Group A (MP treated) Group B (Isolated PIP)a
Injection Number
First Second Third Last
Injection Number
Fig. 3 Changes in fixed-flexion contracture (a) and range of motion
(b) of proximal interphalangeal joint contractures by group and
collagenase Clostridium histolyticum injection. FFC fixed-flexion
contracture, MP metacarpophalangeal, PIP proximal interphalangeal,
ROM range of motion
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Fig. 4 Fixed-flexion contracture (a) and range of motion (b) at baseline and day 30 by group. FFC fixed-flexion contracture,
MP metacarpophalangeal, PIP proximal interphalangeal, ROM range of motion
Table 2 Goniometry results for fixed-flexion contracture and range of motion at baseline and day 30 by collagenase Clostridium histolyticum
injection number and group
Injection Group Aa Group Bb
Joints (n) Baseline Day 30 Joints (n) Baseline Day 30
FFC
First 201 48.2 ± 20.2 19.2 ± 22.4 376 49.7 ± 18.5 24.4 ± 21.4
Second 75 55.6 ± 19.4 21.6 ± 20.9 147 57.5 ± 16.9 28.5 ± 20.0
Third 33 59.7 ± 18.9 27.4 ± 24.4 62 60.5 ± 14.5 30.2 ± 19.6
Last 201 48.2 ± 20.2 13.3 ± 19.4 376 49.7 ± 18.5 20.1 ± 20.4
ROM
First 197c 43.1 ± 18.9 71.0 ± 22.2 372d 49.9 ± 19.6 74.0 ± 23.0
Second 74c 37.2 ± 17.8 70.6 ± 20.8 145 41.3 ± 17.2 69.5 ± 22.3
Third 33 33.5 ± 16.8 64.1 ± 22.9 61d 37.5 ± 16.1 69.3 ± 20.3
Last 197c 43.1 ± 18.9 77.5 ± 19.4 372d 49.9 ± 19.6 78.8 ± 22.0
Results are mean ± SD ()
CCH collagenase Clostridium histolyticum, FFC fixed-flexion contracture, ROM range of motion
a Group A: patients with MP and PIP joint contractures in the same finger, but only the cord affecting the MP joint was treated with CCH
b Group B: patients had isolated PIP joint contracture (or PIP contracture combined with an MP joint contracture \20), and only the cord
affecting the PIP joint was treated with CCH
c Day 30, n = 199 (first), 75 (second), 199 (last)
d Day 30, n = 374 (first), 62 (third), 373 (last)
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Interestingly, in both groups, there was a small decrease
in the percentage of PIP joint contractures that were cor-
rected or showed improvement after the second CCH
injection. This could be due—at least in part—to some
residual AEs at the injection site, including edema and
stiffness. Overall, 46 % of MP/PIP joint contractures
(Group A) and 44 % of isolated PIP contractures (Group B)
received only one CCH injection.
In both Groups A and B, the relative (percentage)
changes in FFC decreased slightly between the first and
third CCH injections. Pre-injection FFC measures were
quite similar between Groups A and B, and baseline values
increased slightly before the second and then the third
injections in both groups. Baseline FFC was lowest before
the last injection in both groups. Overall, reductions in FFC
were slightly larger among PIP joints in Group A versus
Group B at each timepoint, as shown in Fig. 3 and by the
slopes of the lines in Fig. 4a. Similarly, changes in ROM
were slightly larger in Group A versus Group B. A
potential explanation may be related to the mechanics of
the entire digit. By releasing two joints, the overall benefit
for movement could be larger than the sole improvement in
the measure of FFC. Although the treated joint may remain
stiff or swollen, the released joint could be moving freely.
It is feasible that releasing a proximal cord may reduce
some of the tension affecting more distal joints, allowing
for improvement along the entire digit. In Group B, the
largest change in ROM was observed after the third
injection. Overall, regardless of the type or number of CCH
injections received, all of the changes in ROM can be
considered clinically meaningful. In all but one instance,
the change in ROM was twofold larger than the previously
demonstrated clinically important difference (CID) of
13.5 (95 % CI 11.9–15.1) [12]. The CID is calculated
statistically, but it can help interpret the clinical relevance
of changes in objective measures from the patient’s per-
spective [13, 14].
The vast majority of patients experienced C1 AE during
the studies; most events were injection-site reactions,
including edema, pain, hemorrhage, and swelling. Most
AEs were mild and transient in nature. Although slightly
larger percentages of patients in the PIP joint contracture
subgroups experienced AEs compared with all patients,
these differences are not likely to be clinically relevant. As
reported for the CORD [7, 8] and JOINT [9] studies, the
types, frequencies, and severity of AEs were comparable
with those in other published research on the safety and
tolerability of CCH.
To our knowledge, this is the first report of spontaneous
correction and improvement in PIP joint contractures after
treatment of an MP joint contracture in the same finger.
Thus, it is not possible to discuss the findings as they relate
to the extant literature. However, the body of evidence
describing the overall results of surgical or non-surgical
interventions for DC is large. In a systematic review of
fasciotomy and fasciectomy among European patients,
more MP than PIP joint contractures met the pre-specified
outcome, with mean improvements of 80 and 49 % after
Table 3 Adverse events occurring in C10 % of patients
Adverse event Groups Aa/Bb (N = 616) All patients (N = 961)
Patients with C1 adverse event 604 (98) 934 (97)
General and injection-site conditions
Edema peripheral 500 (81) 736 (77)
Injection-site pain 239 (39) 381 (40)
Injection-site hemorrhage 231 (38) 359 (37)
Tenderness 181 (29) 250 (26)
Injection-site swelling 170 (28) 255 (27)
Contusion 402 (65) 574 (60)
Pain in extremity 263 (43) 383 (40)
Pruritus 94 (15) 122 (13)
Ecchymosis 87 (14) 125 (13)
Skin laceration 79 (13) 106 (11)
Blood blister 70 (11) 79 (8)
Lymphadenopathy 67 (11) 86 (9)
Data are given as n (%)
CCH collagenase Clostridium histolyticum, MP metacarpophalangeal, PIP proximal interphalangeal
a Group A: patients with MP and PIP joint contractures in the same finger, but only the cord affecting the MP joint was treated with CCH
b Group B: patients had isolated PIP joint contracture (or PIP contracture combined with an MP joint contracture \20), and only the cord
affecting the PIP joint was treated with CCH
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fasciotomy and 94 and 66 % after fasciectomy, respec-
tively [15]. Salhi et al. [16] reported similar results in a
systematic review of PNF. In a more recently published
study comparing outcomes of PNF versus limited fasciec-
tomy, van Rijssen et al. [17] showed that 55 % of MP and
26 % of PIP joints corrected to B5 at 6 weeks after PNF;
94 % of MP and 47 % of PIP joints corrected after limited
fasciectomy. In another recent study, Shin and Jones [18]
showed that [90 % of MP and 82 % of PIP joints were
fully corrected at least 2 weeks after segmental
fasciectomies.
Thus, the relative efficacy of different treatment options
for correcting MP versus PIP joint contractures is well-
established: PIP joints are less responsive to intervention,
become even more so over time, and are more susceptible
to recurrence [1, 3]. Fundamental anatomical differences
[3, 19] between the MP and PIP joints play a large part
[20]; other factors not related to Dupuytren’s disease are
also involved, including secondary contraction of the volar
plate and/or collateral ligaments, arthritic changes and
stiffness, and attenuation of the extensor mechanism. Any
one or more of these processes may hold the PIP joint in a
flexed position even after correction of the MP joint con-
tracture or partial correction of the PIP joint contracture.
The irony is that, despite the problematic nature of the
contracted PIP joint and its relative resilience to corrective
intervention, in some cases—as demonstrated here—the
PIP joint contracture resolves spontaneously after treating
an MP joint contracture in the same finger. A plausible
explanation is that some of the CCH spreads across mul-
tiple cords. Alternatively, spontaneous correction of PIP
joint contractures may be facilitated by the finger-extension
procedure. Perhaps it is a combination of both and other
unforeseen factors.
A careful clinical examination is essential for identify-
ing the source and arrangement of the cord or cords causing
the PIP joint deformity. These and other patient clinical
characteristics, including the extent to which hand function
is compromised, should be considered when deciding
whether or not to treat the deformity. If affirmative, these
factors are again considered in deciding on the approach
for corrective intervention. In cases in which the affected
MP and PIP joints are in the same finger, the likelihood of
achieving full correction for both joint contractures is high
after CCH if there is one central, pretendinous cord. If there
is a separate cord affecting just the PIP joint, spontaneous
correction after treating the MP joint contracture is less
likely. Isolated PIP joint contractures are most prevalent in
the fifth finger [21, 22]. Although this is the smallest of the
fingers, it contains one of the largest digital branches of the
ulnar nerve in the hand, which may make the approach to
treatment even more challenging.
The abductor digiti minimi cord is commonly observed
in the fifth finger. As this type of cord is confined to the
finger, PNF is not recommended, although CCH would be a
viable alternative. Moreover, although there is no robust
clinical evidence to suggest that PNF has an increased risk
of iatrogenic nerve, artery or tendon injury, it is reasonable
to imagine that a blind procedure with multiple passes of a
sharp needle would place such structures at risk. Thus,
many surgeons only perform PNF in the palm on well-
defined cords. On occasion during open surgery, after the
pathological tissue has been removed, the contracted PIP
joint can be manipulated straight by the surgeon. In such
cases, the accessory collateral and volar plate are manually
ruptured with controlled pressure.
This exploratory analysis is not without limitations, and
the findings may be most useful for hypothesis generation
and as a resource for the design of future clinical studies.
For example, the clinical trial data were not analyzed by
finger, and details regarding the nature of the cords con-
tracting the MP and/or PIP joints were not available. That
said, most surgical studies also do not report on the detailed
structure of pathological cords—only that they were divi-
ded or excised. Moreover, multiple cords affecting multiple
joints or digits may be excised during a single surgical
session. By contrast, the product label for CCH stipulates a
30-day interval between injections. Of note, a phase III
study evaluating the safety and efficacy of two concurrent
injections into the same hand of patients with multiple
contractures is in progress (ClinicalTrials.gov identifier no.
NCT01407068). Additional studies that investigate differ-
ent treatment paradigms may afford clinicians a better
understanding of these issues. Such designs might include
multiple, simultaneous CCH injections to treat MP and PIP
joint contractures of the same finger or close, sequential
injections to treat residual PIP joint contractures. Finally, it
is important that future studies provide for the collection of
details regarding the pathological anatomy of affected
joints and take these configurations into account when
analyzing the results.
5 Conclusions
The results of this post hoc analysis suggest that the effi-
cacy of CCH for PIP contractures, as reflected by measures
of clinical success and clinical improvement, was compa-
rable after treatment of an MP joint contracture in the same
finger and injection of an isolated PIP joint contracture.
Likewise, improvements in FFC and ROM were quite
similar across the two groups. In both Groups A and B, the
changes in ROM exceeded the CID, which represents a
1-point change on a 4-point scale for patient-reported
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improvement. Thus, regardless of the specific pathological
palmar anatomy, and consistent with previous research
using surgical and non-surgical techniques, some PIP joints
not directly treated with CCH will show meaningful
spontaneous improvements in contracture. Furthermore,
these improvements can be achieved without compromis-
ing safety.
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